Differential expression of novel immunological biomarkers in TILS is associated with improved outcome in advanced triple negative breast cancer resistant to neoadjuvant chemotherapy

Cabioglu N.; Onder S.; Oner G.; Karatay H.; Ozkurt E.; Trablus D. Can; Tukenmez M.; Muslumanoglu M.; Saip P.; Yavuz E.

首页> 外文期刊>The Breast : >Differential expression of novel immunological biomarkers in TILS is associated with improved outcome in advanced triple negative breast cancer resistant to neoadjuvant chemotherapy

【24h】

Differential expression of novel immunological biomarkers in TILS is associated with improved outcome in advanced triple negative breast cancer resistant to neoadjuvant chemotherapy

机译：TILs中新型免疫生物标志物的差异表达与晚期三重阴性乳腺癌的改善结果有关，耐什么乳腺癌对新辅助化疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2019年第2019期|共1页
作者
Cabioglu N.; Onder S.; Oner G.; Karatay H.; Ozkurt E.; Trablus D. Can; Tukenmez M.; Muslumanoglu M.; Saip P.; Yavuz E.;
展开▼
作者单位

Istanbul Univ Surg Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Pathol Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Surg Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Pathol Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Surg Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Surg Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Surg Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Surg Istanbul Fac Med Istanbul Turkey;

Istanbul Univ Inst Oncol Med Oncol Istanbul Turkey;

Istanbul Univ Pathol Istanbul Fac Med Istanbul Turkey;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Differential expression of novel immunological biomarkers in TILS is associated with improved outcome in advanced triple negative breast cancer resistant to neoadjuvant chemotherapy [J] . Cabioglu N., Onder S., Oner G., The Breast : . 2019,第期

机译：TILs中新型免疫生物标志物的差异表达与晚期三重阴性乳腺癌的改善结果有关，耐什么乳腺癌对新辅助化疗
2. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer [J] . Neslihan Cabioglu, Semen Onder, Gizem Oner, BMC Cancer . 2021,第1期

机译：TIM3在TILs上表达与局部晚期三阴性乳腺癌患者对Neoadjuvant化疗的差异有关
3. Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Neoadjuvant化疗后三阴性乳腺癌残留疾病中长期结果的免疫相关性
4. Prediction of Neoadjuvant Chemotherapy Outcome in Breast Cancer Patients [C] . Jose Neves, Almeida Dias, Cristiana Silva, International conference on applied physics, system science and computers . 2019

机译：乳腺癌患者中新辅助化疗结果预测
5. Systems-Based Modeling Approaches for Improving Triple-Negative Breast Cancer Patients' Outcomes [D] . Fleisher, Brett A. 2020

机译：基于系统的改善三重阴性乳腺癌患者结果的建模方法
6. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer [O] . Neslihan Cabioglu, Semen Onder, Gizem Oner, 2021

机译：TIN3 TILS的表达与局部晚期三阴性乳腺癌患者对Neoadjuvant化疗的反应不良有关
7. Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial [O] . S. Loi, P. Schmid, G. Aktan, 2019

机译：肿瘤浸润淋巴细胞（TIL）与PEMBLIZUMAB（PEMBRO）+化疗（CT）作为新辅助乳腺癌（TNBC）的响应（TNBC）的关系（TNBC）：第IB次临时 - 173试验

Differential expression of novel immunological biomarkers in TILS is associated with improved outcome in advanced triple negative breast cancer resistant to neoadjuvant chemotherapy

著录项

相似文献

相关主题

期刊订阅